Northwest Biotherapeutics, Inc. (BST:NBYB)

Market Cap	357.45M -2.9%
Revenue (ttm)	798.61K -41.3%
Net Income	-77.75M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,340
Average Volume	21,522
Open	0.2100
Previous Close	0.2100
Day's Range	0.2100 - 0.2360
52-Week Range	0.1700 - 0.4500
Beta	n/a
RSI	50.96
Earnings Date	Mar 13, 2026

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 25
• Stock Exchange: Stuttgart Stock Exchange
• Ticker Symbol: NBYB

Financial Performance

In 2024, Northwest Biotherapeutics's revenue was $1.38 million, a decrease of -28.47% compared to the previous year's $1.93 million. Losses were -$85.19 million, 32.3% more than in 2023.

Financial numbers in USD